GIGA-2339: safety and drug behavior testing in people with chronic hepatitis B

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 randomized, placebo-controlled trial gives single and multiple intravenous doses of GIGA-2339 to adults with chronic hepatitis B to characterize safety, tolerability, and pharmacokinetics. The study collects serial blood samples for drug levels and closely monitors for adverse events. Eligible participants are HBeAg-negative with specified HBsAg and HBV DNA ranges and may be on stable nucleos(t)ide analogue therapy or not. Dosing and follow-up take place at investigational sites in Arizona and California to gather early human safety and PK data.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Hepatitis B envelope antigen (HBeAg) negative chronic HBV infection for ≥ 6 months, defined as presence of Hepatitis B surface antigen (HBsAg) in serum for ≥ 6 months.
* Serum HBsAg concentration between ≥ 100 international units per milliliter (IU/mL) and 2000 IU/mL at screening.
* Currently on stable dose of nucleot(s)ide analogues (NAs) (≥ 6 months) and expected to continue while participating in the study, or are not received NAs.
* Have serum HBV deoxyribonucleic acid (DNA) concentration ≤ 50 IU/mL at screening (for those who are on NAs); or have serum HBV DNA concentration ≤ 2000 IU/mL at screening (for those who are NOT on NAs).
* Male participants must refrain from donating spermatozoa and agree to use highly effective contraception.
* Female participants must not be pregnant, or breastfeeding; either should not be a woman of childbearing potential (WOCBP) or if WOCBP should use highly effective contraceptive methods.

Key Exclusion Criteria:

* Positive for co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and/or hepatitis D virus (HDV) at screening.
* Participants that weigh less than 50 kilograms (kg) and/or have a body mass index (BMI) less than 18.5.
* History of documented liver cirrhosis at screening. Patients under liver cirrhosis evaluation at screening will not be eligible until cirrhosis is ruled out.
* Liver stiffness \> 8 kilopascal (kPa) at screening.
* History of chronic liver disease from another cause, immune complex disease, or autoimmune diseases that in the opinion of the investigator would preclude participation.
* Family history of hepatocellular carcinoma (HCC).
* Alpha fetoprotein \> 20 nanograms per milliliter (ng/mL).
* Presence of a liver imaging reporting and data system (LI-RADS) 4 or 5 liver lesion on imaging 12 months prior to Screening OR, LI-RADS-US findings of US-3 grade on imaging 12 months prior to Screening, OR LIRADS-US grade 3 done prior to the D1 infusion visit, if prior LI-RADS or LI-RADS-US results are not available at Screening.
* History of hematopoietic stem cell transplant or solid organ transplant.
* Receipt of anti-HBV monoclonal antibody (mAb)/pAb therapy of any kind in the past (including hepatitis B immunoglobulin \[HBIG\]).
* History of cardiovascular disease (e.g., coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long QT syndrome). Stable hypertension is allowed.
* Malignancy diagnosed and/or treated within 5 years prior to Screening, and/or with ongoing treatment for malignancy, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.
* Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors, or anti-platelet agents like clopidogrel).
* Male participants with a corrected QT interval using Fridericia's formula (QTcF) \> 450 milliseconds (msec) and female participants with QTcF \> 470 msec on ECG recorded at screening. if the participant has evidence of an intraventricular conduction delay, defined as QRS interval greater than 110 msec, a QTcF is \> 500 msec for both males and females will be excluded.
* Known hypersensitivity to any GIGA-2339 excipients or any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (nonactive hay fever is acceptable), or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates participation.
* Received or will receive live-attenuated virus vaccinations such as measles, mumps, rubella or varicella within 4 weeks before and up to three months after administration of investigational product (IP).

Where it's running

• Grifols Investigative site
  Chandler, Arizona, United States Recruiting
• Grifols Investigative site
  Huntington Beach, California, United States Recruiting
• Grifols Investigative site
  Lake Forest, California, United States Recruiting
• Grifols Investigative site
  Long Beach, California, United States Recruiting
• Grifols Investigative Site
  Peachtree Corners, Georgia, United States Recruiting
• Grifols Investigative Site
  Iowa City, Iowa, United States Recruiting

Study contacts

• Study coordinator: Enrikas Vainorius, MD
• Email: giga2339study@grifols.com
• Phone: +1 919-316-6396

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Germinal center immune response in chronic hepatitis B

  We will see if the structure and B-cell activity in germinal centers differ between people with chronic hepatitis B and people without by analyzing blood and discarded surgical tissues.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07240350

• Hepatitis B vaccination for newborns after surgery

  This study looks at how safe and effective it is to give hepatitis B vaccinations to newborns who have had surgery, to help find the best timing for these shots.

  Recruiting Children's Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT06023056

• Registry for patients with hepatitis B virus infection

  This study is collecting information from people with hepatitis B to better understand the virus and find out who might be interested in trying new treatments like vaccines.

  Recruiting Hannover Medical School · Hanover · NCT05051098

• Evaluating new biomarkers for chronic Hepatitis B infection management

  This study is testing new blood markers to see if they can help doctors better manage chronic Hepatitis B and predict serious health issues for patients receiving care at a hospital.

  Recruiting Assistance Publique - Hôpitaux de Paris · Créteil, Créteil · NCT06906016

• Non-invasive approach to assess liver fibrosis in chronic hepatitis B patients

  This study is testing a new way to see if liver stiffness measurements can help predict if liver damage improves in people with chronic hepatitis B who have been treated with antiviral therapy.

  Recruiting Beijing Friendship Hospital · Beijing · NCT06874127

• Evaluating a new combination therapy for chronic Hepatitis B infection

  This study is testing a new combination treatment for adults with chronic Hepatitis B who are already on medication to see if it works better than the standard treatment alone.

  Recruiting at 14 sites Phase 2 Brii Biosciences Limited · Beijing, Beijing Municipality and 13 other locations · NCT06650852

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.